A Gd-doped polydopamine (PDA)-based theranostic nanoplatform as a strong MR/PA dual-modal imaging agent for PTT/PDT synergistic therapy. Issue 7 (2nd February 2021)

• Record Type: Journal Article
• Authors: Pu, Yiyao; Zhu, Yuda; Qiao, Zi; Xin, Nini; Chen, Suping; Sun, Jing; Jin, Rongrong; Nie, Yu; Fan, Hongsong
• Is Part Of: Journal of materials chemistry. Volume 9:Issue 7(2021)
• Page Start: 1846
• Page End: 1857
• Publication Date: 2021-02-02
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d0tb02725a
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : The construction of a Gd–PDA-Ce6@Gd-MOF (GPCG) theranostic nanosystem which shows enhanced MR/PA imaging performance with great cancer photothermal/photodynamic synergistic therapeutic efficiency under 808/660 nm double laser irradiation. Abstract : Based on widely used photoacoustic imaging (PAI) and photothermal properties of polydopamine (PDA), a multifunctional Gd–PDA-Ce6@Gd-MOF (GPCG) nanosystem with a core–shell structure and strong imaging ability was constructed. Benefitting from the metal–organic framework (MOF) structure, GPCG nanoparticles (NPs) showed enhanced magnetic resonance imaging (MRI) ability with high relaxation rates ( r 1 = 13.72 mM −1 s −1 and r 2 = 216.14 mM −1 s −1 ). The MRI effect of Gd ions combined with the PAI effect of PDA, giving GPCG NPs a dual-modal imaging ability. The core, mainly composed of PDA and photodynamic photosensitizer chlorin e6 (Ce6), achieved photothermal/photodynamic therapy (PTT/PDT) synergistic performance. Besides, to overcome the unexpected release of Ce6, the MOF shell realized pH-sensitive release and a high local concentration. Through in vivo studies, we concluded that GPCG NPs show a good inhibitory effect on tumor growth. In conclusion, we successfully obtained a GPCG theranostic nanoplatform and paved the way for subsequent design of imaging guided therapeutic nanostructures based on metal-doped PDA.